Canaccord Genuity Reiterates “Buy” Rating for NPS Pharmaceuticals (NPSP)
Several other analysts have also recently commented on the stock. Analysts at FBR Capital Markets initiated coverage on shares of NPS Pharmaceuticals in a research note on Thursday. They set an “outperform” rating and a $34.00 price target on the stock. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of NPS Pharmaceuticals in a research note on Thursday, August 7th. They now have a $26.00 price target on the stock, up previously from $25.00. Finally, analysts at Janney Montgomery Scott initiated coverage on shares of NPS Pharmaceuticals in a research note on Thursday, May 22nd. They set a “buy” rating and a $37.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. NPS Pharmaceuticals presently has an average rating of “Buy” and an average price target of $39.23.
NPS Pharmaceuticals (NASDAQ:NPSP) traded down 1.62% during mid-day trading on Friday, hitting $26.73. 548,273 shares of the company’s stock traded hands. NPS Pharmaceuticals has a 52-week low of $21.60 and a 52-week high of $39.68. The stock’s 50-day moving average is $29.64 and its 200-day moving average is $30.71. The company has a market cap of $2.848 billion and a P/E ratio of 1358.50.
NPS Pharmaceuticals (NASDAQ:NPSP) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.02 earnings per share (EPS) for the quarter. The company had revenue of $56.10 million for the quarter, compared to the consensus estimate of $53.06 million. During the same quarter in the previous year, the company posted ($0.13) earnings per share. The company’s revenue for the quarter was up 53.7% on a year-over-year basis. On average, analysts predict that NPS Pharmaceuticals will post $0.02 earnings per share for the current fiscal year.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.